QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:CLXT

Calyxt (CLXT) Stock Forecast, Price & News

$0.32
-0.03 (-8.56%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.29
$0.41
50-Day Range
$0.29
$1.55
52-Week Range
$0.27
$5.42
Volume
11.52 million shs
Average Volume
559,414 shs
Market Capitalization
$13.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.12
30 days | 90 days | 365 days | Advanced Chart
Receive CLXT News and Ratings via Email

Sign-up to receive the latest news and ratings for Calyxt and its competitors with MarketBeat's FREE daily newsletter.

Calyxt logo

About Calyxt

Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Agricultural chemicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLXT
Fax
N/A
Employees
55
Year Founded
N/A

Sales & Book Value

Annual Sales
$25.99 million
Book Value
$0.37 per share

Profitability

Net Income
$-29.20 million
Net Margins
-114.68%
Pretax Margin
-112.36%

Debt

Price-To-Earnings

Miscellaneous

Free Float
42,084,000
Market Cap
$13.70 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/16/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

592nd out of 1,423 stocks

Agricultural Chemicals Industry

6th out of 13 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -













Calyxt (NASDAQ:CLXT) Frequently Asked Questions

Is Calyxt a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Calyxt in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Calyxt stock.
View analyst ratings for Calyxt
or view top-rated stocks.

Are investors shorting Calyxt?

Calyxt saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 210,200 shares, a decrease of 14.4% from the April 15th total of 245,600 shares. Based on an average daily volume of 504,600 shares, the short-interest ratio is presently 0.4 days. Currently, 1.2% of the company's shares are short sold.
View Calyxt's Short Interest
.

When is Calyxt's next earnings date?

Calyxt is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Calyxt
.

How were Calyxt's earnings last quarter?

Calyxt, Inc. (NASDAQ:CLXT) issued its earnings results on Thursday, May, 5th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. Calyxt had a negative net margin of 114.68% and a negative trailing twelve-month return on equity of 174.13%. During the same quarter last year, the business earned ($0.24) EPS.
View Calyxt's earnings history
.

What price target have analysts set for CLXT?

2 brokerages have issued 12 month target prices for Calyxt's stock. Their forecasts range from $4.00 to $10.00. On average, they anticipate Calyxt's stock price to reach $7.00 in the next year. This suggests a possible upside of 2,085.5% from the stock's current price.
View analysts' price targets for Calyxt
or view top-rated stocks among Wall Street analysts.

Who are Calyxt's key executives?
Calyxt's management team includes the following people:
  • Mr. William F. Koschak, Chief Financial Officer (Age 53, Pay $481.46k) (LinkedIn Profile)
  • Dr. Travis J. Frey Ph.D., Chief Technology Officer (Age 44, Pay $426.76k)
  • Mr. Michael Allen Carr, Pres, CEO & Director (LinkedIn Profile)
  • Dr. Daniel F. Voytas Ph.D., Founder, Chief Science Officer & Chair of Scientific Advisory Board (Age 59)
  • Ms. Debra H. Frimerman, Gen. Counsel & Corp. Sec. (Age 42)
  • Trina Lundblad, Director of Communications
  • Dr. Stephen M. Bravo, Chief Medical Officer
  • Mr. Gerry Nuovo, Sr. VP of Bus. Devel.
What other stocks do shareholders of Calyxt own?
When did Calyxt IPO?

(CLXT) raised $101 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,100,000 shares at $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

What is Calyxt's stock symbol?

Calyxt trades on the NASDAQ under the ticker symbol "CLXT."

Who are Calyxt's major shareholders?

Calyxt's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (2.57%), Nikko Asset Management Americas Inc. (2.57%), Vanguard Group Inc. (0.64%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Calyxt stock include Andre Choulika, Christopher J Neugent, Daniel F Voytas, James Blome, Michael A Carr, Philippe Dumont, Travis Frey, William Koschak and Yves J Ribeill.
View institutional ownership trends for Calyxt
.

Which institutional investors are selling Calyxt stock?

CLXT stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., and Simplex Trading LLC.
View insider buying and selling activity for Calyxt
or view top insider-selling stocks.

How do I buy shares of Calyxt?

Shares of CLXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calyxt's stock price today?

One share of CLXT stock can currently be purchased for approximately $0.32.

How much money does Calyxt make?

Calyxt has a market capitalization of $13.70 million and generates $25.99 million in revenue each year. The company earns $-29.20 million in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Calyxt have?

Calyxt employs 55 workers across the globe.

What is Calyxt's official website?

The official website for Calyxt is www.calyxt.com.

How can I contact Calyxt?

Calyxt's mailing address is 2800 MOUNT RIDGE ROAD, ROSEVILLE MN, 55113. The company can be reached via phone at (651) 683-2807 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.